**Statistical analysis plan**
Efficacy analyses will be perfomed on per-protocol set (PPS) which consists of all randomized patients without major protocol violation and with a sufficient exposure to study treatment (at least five treatment sessions). The primary efficacy analysis will be the comparison between CT+tDCS and CT alone and the primary endpoint will be RBANS total scores change from baseline to the end of double-blind phase. Safety analyses set will include all patients who were randomized and received at least one study session.
Demographic and clinical characteristics among groups will be compared by an one-way analysis of
variance (ANOVA), Kruskal-Wallis test or by a chi-square test as appropriate. The primary and secondary efficacy endpoints (cognitive performance and psychopathology) will be analyzed using the separate repeated measures analyses of variance (RM-ANOVAs) with correction for nonsphericity and post-hoc tests when necessary. To control an influence of confounding variables if different between groups (PANSS), primary efficacy endpoint will be subjected to analyses of covariance (ANCOVA). The effect size (between-group difference) will be calculated as Hedges´ g. Early termination (less than five completed session) rate and presence of side effects across groups will be compared by chi-square test.